Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Income Statement [Abstract]
Revenue	$ 42,612	$ 42,366
Cost of goods sold	13,970	14,425
Gross profit	28,642	27,941
Operating expenses:
Research and development	5,530	7,846
Clinical and regulatory affairs	3,835	3,884
Marketing and sales	25,900	27,918
General and administrative	8,873	9,946
Restructuring costs	166	7,323
Settlement costs	0	4,650
Contract termination and business acquisition expenses	0	4,778
Total operating expenses	44,304	66,345
Loss from operations	(15,662)	(38,404)
Other income (expense):
Interest income	44	62
Interest expense	(4,295)	(3,782)
Other expense, net	(47)	(356)
Change in fair value of contingent consideration related to acquisition	(1,200)	0
Change in fair value of derivative liabilities	0	(5,088)
Total other income (expense)	(5,498)	(9,164)
Net loss before income tax expense	(21,160)	(47,568)
Income tax expense	(154)	(103)
Net loss	(21,314)	(47,671)
Other comprehensive income (loss) foreign currency translation	356	(105)
Comprehensive loss	$ (20,958)	$ (47,776)
Basic and diluted net loss per share (in dollars per share)	$ (0.26)	$ (0.62)
Shares used in computing basic and diluted net loss per share (in shares)	82,928	76,661